[Trimetazidine in correction of chronic heart failure in patients with ischemic heart disease].

Abstract

Twenty patients with NYHA class II-IV heart failure and ejection fraction below 40% received standard therapy (control period) or standard therapy plus open trimetazidine (20 mg t.i.d.) for 3 months in a cross-over design. Therapy with trimetazidine was associated with attenuation of clinical signs of heart failure (average NYHA class 2.90-/+0.10, 2.27-/+0… (More)

Topics

Cite this paper

@article{Nedoshivin2002TrimetazidineIC, title={[Trimetazidine in correction of chronic heart failure in patients with ischemic heart disease].}, author={A O Nedoshivin and Anastasiya Kutuzova and I. V. Nesterova and I E Mikhaĭlova and E I Rubashkina and N. A. Novikova and E A Liasnikova and N B Perepech}, journal={Kardiologiia}, year={2002}, volume={42 3}, pages={12-5} }